PDF(Pubmed)
Abstract：
UNASSIGNED: This comprehensive review was conducted to assess the effects of tranexamic acid (TXA) on blood loss, venous thromboembolism (VTE) risk, and wound complications following total hip arthroplasty (THA). Additionally, it sought to evaluate the effects of various TXA dosages, modes of administration, and combinations with other antifibrinolytic drug.
UNASSIGNED: In search of systematic reviews and meta-analyses on the use of TXA in THA patients, we searched extensively through databases including Scopus, the Cochrane Library, Embase, Medline, the Web of Science, PubMed, and Google Scholar. We discovered 23 meta-analyses covering 32,442 patients overall that fulfilled our study criteria, spanning the period from the creation of these databases until May 2023.
UNASSIGNED: This comprehensive review\'s meta-analyses, which together examined over 35,000 patients, repeatedly demonstrated how TXA administration during THA successfully lowers perioperative blood loss and the need for transfusions. TXA reduced total blood loss by an average of 151-370 ml, postoperative hemoglobin levels by 0.5-1.1 g/dL, and transfusion rates by 19-26% on average when compared to control groups. The information gathered did not indicate that using TXA significantly increased the risk of VTE or wound complications. When comparing different TXA doses, administration techniques, or its use in conjunction with other anti-fibrinolytic therapies, no discernible differences were found in terms of efficacy or safety outcomes.
UNASSIGNED: The comprehensive review clearly indicates that TXA improves THA outcomes without increasing the risk of adverse events by lowering blood loss and the requirement for transfusions. This insightful information can help surgeons decide whether to use TXA during THA procedures.
UNASSIGNED: In search of systematic reviews and meta-analyses on the use of TXA in THA patients, we searched extensively through databases including Scopus, the Cochrane Library, Embase, Medline, the Web of Science, PubMed, and Google Scholar. We discovered 23 meta-analyses covering 32,442 patients overall that fulfilled our study criteria, spanning the period from the creation of these databases until May 2023.
UNASSIGNED: This comprehensive review\'s meta-analyses, which together examined over 35,000 patients, repeatedly demonstrated how TXA administration during THA successfully lowers perioperative blood loss and the need for transfusions. TXA reduced total blood loss by an average of 151-370 ml, postoperative hemoglobin levels by 0.5-1.1 g/dL, and transfusion rates by 19-26% on average when compared to control groups. The information gathered did not indicate that using TXA significantly increased the risk of VTE or wound complications. When comparing different TXA doses, administration techniques, or its use in conjunction with other anti-fibrinolytic therapies, no discernible differences were found in terms of efficacy or safety outcomes.
UNASSIGNED: The comprehensive review clearly indicates that TXA improves THA outcomes without increasing the risk of adverse events by lowering blood loss and the requirement for transfusions. This insightful information can help surgeons decide whether to use TXA during THA procedures.
摘要：
■进行了这项全面审查，以评估氨甲环酸（TXA）对失血的影响，静脉血栓栓塞(VTE)风险,全髋关节置换术（THA）后的伤口并发症。此外,它试图评估各种TXA剂量的效果，管理模式，以及与其他抗纤维蛋白溶解药物的组合。
■在THA患者中使用TXA的系统评价和荟萃分析中，我们通过包括Scopus在内的数据库进行了广泛的搜索，Cochrane图书馆,Embase,Medline,WebofScience,PubMed,谷歌学者。我们发现了23项荟萃分析，涵盖了32,442名患者，这些患者符合我们的研究标准，从这些数据库的创建到2023年5月。
■这篇综合综述的荟萃分析，总共检查了超过35,000名患者，反复证明在THA期间给予TXA如何成功降低围手术期失血量和输血需求。TXA减少总失血量平均151-370毫升，术后血红蛋白水平0.5-1.1g/dL，与对照组相比，输血率平均为19-26%。收集的信息并未表明使用TXA显着增加了VTE或伤口并发症的风险。当比较不同的TXA剂量时，管理技术，或与其他抗纤维蛋白溶解疗法结合使用，在疗效或安全性结局方面没有发现明显差异.
■全面审查清楚地表明，TXA通过降低失血量和输血需求，在不增加不良事件风险的情况下改善了THA结果。这些有见地的信息可以帮助外科医生决定在THA手术期间是否使用TXA。
■在THA患者中使用TXA的系统评价和荟萃分析中，我们通过包括Scopus在内的数据库进行了广泛的搜索，Cochrane图书馆,Embase,Medline,WebofScience,PubMed,谷歌学者。我们发现了23项荟萃分析，涵盖了32,442名患者，这些患者符合我们的研究标准，从这些数据库的创建到2023年5月。
■这篇综合综述的荟萃分析，总共检查了超过35,000名患者，反复证明在THA期间给予TXA如何成功降低围手术期失血量和输血需求。TXA减少总失血量平均151-370毫升，术后血红蛋白水平0.5-1.1g/dL，与对照组相比，输血率平均为19-26%。收集的信息并未表明使用TXA显着增加了VTE或伤口并发症的风险。当比较不同的TXA剂量时，管理技术，或与其他抗纤维蛋白溶解疗法结合使用，在疗效或安全性结局方面没有发现明显差异.
■全面审查清楚地表明，TXA通过降低失血量和输血需求，在不增加不良事件风险的情况下改善了THA结果。这些有见地的信息可以帮助外科医生决定在THA手术期间是否使用TXA。
